Iadademstat (ORY-1001) is an LSD1 inhibitor in phase 2 clinical trials in leukemia (NCT05546580) that has been shown to reactivate Notch signaling, thereby suppressing ASCL1 activity and reducing tumor growth in SCLC mouse models [43]. Here, ASCL1 is linked to small cell lung carcinoma.